Creation
Draft
Initial
Detailed
Accepted
Adoption
Idea Description
Supplementary Information
Innovation 'Elevator Pitch':
UK developed patient focused Population Health solution pulls cross sector data (i.e. GP, Acute, Mental health, etc) and performs analytics and intelligent cohort finding that can identify patients with reported unexplained symptoms.
Overview of Innovation:
ArtemusICS supports a health system to analyse population data and identify specific gaps, health inequalities and unwarranted variations in its population’s health. ArtemusiCS secure web accessed hosted system provides a wide range of tools, dashboards, selection and filtration options to identify and create patient cohorts. ArtemusICS can then further identify costs, utilisation and gaps in care.

Collecting data from Acute, GP, Community, Mental, Social and Ambulance, ArtemusICS provides commissioners and providers with a tool to identify cohorts of patients, and understand the integrated care needs of a population right down to an individual. It contains analytical tools to allow for LTC risk, EOL risk, Frailty, Social isolation, etc to be collated and presented in one picture. It also allows for evaluation of interventions (i.e outcomes) and identification of RoI.

It has a unique attributes based architecture, where all data items are linked to one or more “attributes”, based on their coding (i.e. Snomed, Read, ICD10, etc). Inherently future proof and expandable, it allows us to utilise Machine Learning and AI techniques to drill through large data sets to find correlations and trends in specified data types, such as the symptoms presented in the MUS cohorts.

ArtemusICS operates on three distinct levels:
  • Overview Dashboards: provide whole-population analytics with facilities to filter down to key patient cohorts. A range of Dashboards provides commissioners and clinicians pertinent population count, event counts, service and usage counts and costs; with the facility to then drill through to cohort and patient specific views.
  • Cohort Manager enables the user to review sub-lists of patients, caseload management groups or individual patients against a range of detailed views including conditions, events, measures, timelines and management lists. Venn diagrams offering cohort comparisons to enable care planners and clinicians to pin-point a specific cohort with a specific set of attributes for intervention and care management.
  • Patient view provides a range of views specific to patient conditions, medications, diagnosis, events and measures, supporting the clinical user to improve diagnosis and plan care.
In addition, our remote monitoring technology can also collect surveys such as PHQ,GAD7, HADs etc
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content4
Innovation 'Elevator Pitch':
PredictX Machine Learning system has been successfully deployed to solve a similarly difficult problem of identifiying School Ready Children. This model is ideal for solving the problem of early identification of MUS.
Overview of Innovation:
The Complex Symptoms Service (CSS) will focus on the problem of MUS following on from the success of the BMUSS Phase 1 pilot. A system that automatically segments and identifies patients with high probability of MUS at an early stage will significantly increase the savings realised of the CSS as well as improve the well-being of patients. The complexity of MUS makes it difficult to identify manually especially at early stage.

Machine Learning (ML) has advanced to a stage that the challenging task of identifying Medically Unexplained Symptoms (MUS) automatically is now possible.

Our ML model can infer & predict results even with large variety of causal factors and disparate source data and where a single data point in isolation is a poor indicator. In the case of some long term conditions such as diabetes, a single source such as blood sugar levels can be a confirmatory indicator. MUS suffers from the fact that one episode whether via GP assessment or hospital admission does not indicate MUS on its own. Instead, it takes multiple events and episodes examined together in a holistic model that indicates the probability of MUS.

If a system could identify MUS with minimal historical data, early intervention avoids much more serious and costly problems later on. ML models such as the one PredictX developed for Essex County Council (see attachments) is ideal for working on a large range of data sets and inferring relationships not obvious to human observers.

An accurate MUS identification system must be able to meet several requirements.
  1. Robustness of the model. The model must adapt to differences in local data availability and preserve the accuracy by using proxy data if core data is missing.
  2. Leverage a wide range of data sources including social care and health
  3. Capability to read, understand, and classify free text information in any format including PDF as the source data management is often a challenge.
The PredictX Risk model deals with all of the issues. ML models are utilised not just for the forecasting models but also to facilitate understanding of free text utilising advances in Natural Language Processing (NLP).

The model has further advantage of having real-world analogues & explanability.  There could be a direct relationship from the features to the phenotypes greatly aiding the health professionals responsible for the interventions.

The model has effectively been deployed in a similar context at Essex CC.https://youtu.be/3J2S82vjb8U
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The direction of Travel for the NHS is the attention to early identification and treatment of disease and chronic conditions. As MUS is so difficult to identify at an early stage, patients can ricochet around the system for years before the correct diagnosis is made. MUS is a pervasive condition which has significant implications for cost and resource consumption in the system. MUS accounts for 11 % of the NHS budget for adults and comprises up to 50% of new hospital outpatient visits.

This figure is 11% of total NHS spend. The related cost to the economy in terms of sickness absences and restrictions to quality of life for people with MUS accounts for over £14 billion per annum to the UK economy.

The Complex Symptoms Service is  estimated to save in excess of £750,000 per year, based on data from local pilot services and NHS research studies. This estimate is based on current patient identification methods which logically will identify only a subset of patients at an early stage. A system that automatically identifies MUS patients at an early stage will increase the pool of patients where the interventions have greater impactability.

The value to patients who can benefit from early intervention will be measured in better quality of life, less days in hospital and improved outcomes.
 
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
The West Midlands population is uniquely positioned to benefit from the System. Instead of introducing a new system before the delivery mechanism has been tested and rolled-out. The West Midlands have already mobilised dedicated services for intervening in MUS cases via the  Birmingham Medically Unexplained Symptoms Service (BMUSS), phase 1 and 2.

The service successfully implemented evidence–based practice for MUS, targeting mild, moderate and severe MUS based on a stepped care model. As the infrastructure for impacting patients with MUS have been set-up, tested and proven to be effective, the stage is set for enlarging the funnel and treating more patients with MUS at an early stage.
The system will be effective at identifying patients with MUS at an early stage. Identification alone will be ineffective without the capacity for impactful intervention. The West Midlands deployment will combine both the capacity for early identification with the capacity for intervention.

The close and strategic working relationship established over many years between PredictX and the Midlands and Lancashire CSU will help to ensure that projects are executed per agreed scope and delivered on time and on budget.
 
Current and planned activity: 
PredictX works with the NHS at several levels currently. We work directly with Provider Trusts such as UCLH supplying them with advanced analytic solutions. We also work with CCGs and STPs focusing on advanced analytics that need to integrate social care and health information. We also have a strategic partnership with the West Midlands CSU working to serve their CCG members as well as investing in research and development efforts to apply Artificial Intelligence and Machine Learning techniques to address challenges the sector faces. This partnership has recently been codified with the launch of the Midlands and Lancashire Innovation Partnership - a partnership of the CSU, private sector and academia working together to deliver advanced, AI-enabled solutions.
What is the intellectual property status of your innovation?:
The IPR of our innovation is held 100% by PredictX. We are happy to co-invent new IPR and contribute to the sector.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Innovation 'Elevator Pitch':
Our expert people and advanced health analytics reveal insights from complex data that enable health & care professionals working across the West Midlands to make better decisions for the patients and populations they serve.
Overview of Innovation:
Sollis and the world-renowned Johns Hopkins University have collaborated to produce a population health analytics platform that helps health & care professionals transform services for patients and populations.
 
Sollis Clarity and The Johns Hopkins  ACG ®System is a person-focused case-mix system that captures the multi-dimensional nature of an individual’s health. It considers the total disease experience of each patient, including the implications of co-occurring disease, encouraging a holistic view of the patient rather than the management of specific diseases or episodes.
 
Sollis Clarity supports:
  • Case Finding - Patient level risk stratification
  • Resource Management - Case-mix risk adjustment and benchmarking
  • Population Health Needs Assessment - Population level risk stratification
  • Fair Shares Budgeting - Capitated budget setting
 
Sollis Clarity delivers robust business analytics and data management to identify and analyse populations across the continuum of care to help health & care providers and commissioners get a precise understanding of patterns of mult-morbidity across populations and its relationship to utilisation, costs and outcomes.
 
Sollis Clarity delivers insights into the morbidity patterns of different populations, supporting population health management, service transformation, integrated care and, ultimately, better outcomes for patients.
 
Sollis Clarity goes beyond patient level risk stratification. Risk stratification at a population level helps the health economy — providers and commissioners — analyse and minimise the progression of diseases and the exacerbation of co-morbidities. When combined with the ACG System it is a comprehensive family of measurement tools designed to help explain and predict how healthcare resources are delivered and consumed.
 
Sollis Clarity provides the evidence base to support:
  • Planning and service re-design
  • Clinical decision making
  • Outcomes-based commissioning
  • Risk stratification and predictive modelling
  • Population profiling / segmentation
  • Case-mix adjusted benchmarking
  • Integrated multi-disciplinary care
To view Sollis - Nigel's Story - click here.
To view UK Healthcare data analytics for NHS CCGs - click here.
To view The Proactive Care at Brighton & Hove - click here.
To view Population Profiling at NHS Slough CCG - click here.
To view Using Data to Gain Greater Insight - click here.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wealth creation / Digital health
Benefit to NHS:
Population health analytics delivers an evidence base (insights from data) that supports large scale health & care service transformation. It is an essential component of any Population Health Management strategy and as such underpins the journey to a fully fledged Accountable Care System (ACS).

The Sollis Clarity health analytics platform is a modular system with mix-and-match components to help you achieve your healthcare analysis and commissioning/budgeting requirements.
 
Population health management helps Health & Care stakeholders identify and quantify the drivers and outcomes for addressing the needs of local populations.
 
Led by directors with decades of NHS experience, Sollis analytics software and professional services have been used to analyse data on nearly half the population of England. We believe patient-centred care strategies based on the needs of local populations provide the key to better population health management.
 
Sollis Clarity is helping several CCGs in the UK to implement new reporting and service planning initiatives.  To view examples of ‘Service Transformation: Stories from the CCG Frontline’ summarising how CCGs are using the insights provided by Clarity Patients and ACG® System analysis for service planning and transformation – click here.
 
The Sollis Clarity health analytics platform has two distinct but complementary solutions — Clarity Patients and Clarity Finance — address population health management and financial analysis respectively.
 
Clarity Patients, combined with the Johns Hopkins ACG® System, provides a comprehensive family of measurement tools that helps explain how healthcare resources are delivered and consumed. It supports new commissioning models such as Commissioning for Value, Outcomes Based Commissioning and Year‑of‑Care Commissioning. It delivers analytics that provide insights to support health & care interventions and innovation and it will help you track the success — or otherwise — of those innovations over time.
 
Clarity Finance provides contract management and activity costing with multiple tariffs, giving you business critical evidence on which to base commissioning decisions. It enables you to store and compare different versions of cost and volume type tariffs as well as non-activity tariffs, such as year of care or outcome based currencies, to give you insights on the most effective commissioning decisions.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Knowledge of the risk profile of the region’s population (based around a population segmentation approach) will help Health & Care stakeholders across the West Midlands commission and deliver appropriate preventative services that will drive positive health outcomes for the 'at need' populations of the West Midlands. 

Through the innovative use of information technology to identify patients most in need of an intervention (impactable patient cohorts) Sollis Clarity helps to identify patients who could most benefit from earlier, better informed health care interventions.
 
The Sollis population health analytics platform allows the patient population to be risk assessed to provide timely, evidential data to all members of a Multi-Disciplinary Team (MDT), to include clinicians but not limnited to them. This enables MDT members to provide focused levels of care to specific groups of patients, reducing the risk of a patient’s condition worsening due to it being identified early so assisting MDT members in identifying and improving the care of at-risk patients.
 
Much can be achieved through the acquisition of primary care, secondary care, community care, mental health, prescribing and social care data. It can provide a rich understanding of how healthcare resources are delivered and consumed and by whom. Such analysis can aid an understanding of whether scarce resources are being deployed to those population groups in greatest need.
 
It is important that any population health analysis should focus not on single disease conditions, but on the burden of multi-morbidity observable in a local population.  Population health programmes that have the best chance of success will be those that demonstrate an understanding of the importance of multi-morbidity and its impact on the local health and care economy.
 
Using data to identify early healthcare interventions can provide significant benefits to patients, particularly those with long-term conditions. Providing the functionality to make real time decisions based on clinical evidence will improve outcomes for patients.
 
Sollis exist to help our customers deliver better patient outcomes, better patient experiences at an affordable cost and are wholly focused on the delivery of insights that will help deliver a sustainable and transformed health and care system in the West Midlands.
Current and planned activity: 
We are currently providing analytics support to thirty (30) plus Clinical Commissioning Groups (CCGs) nationally as well as nine hundred (900) plus GP practices and a number of NHS Vanguards, principally Multispecialty Community Providers (MCPs).

We would like to engage with health and care professionals involved in the development and evaluation of New Care Models throughout the West Midlands who want to use evidence based data to understand patterns of multi-morbidity and its relationship to utilisation, costs and outcomes. We are particularly interested in engaging with Sustainability & Transformation Paernerships (STPs) and emerging Accountable Care Systems (ACS).
What is the intellectual property status of your innovation?:
Sollis owns all Intellectual Property (IP) for the following software applications:
  • Sollis Clarity (Population Analytics Platform)
  • Sollis Clarity Patients
  • Sollis Clarity Finance
 Johns Hopkins Health Care (JHHC) owns all Intellectual Property (IP) for the following software:
  • ACG® System
 Also:
  • ISO9001
  • IG Toolkit Certified
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
2
Read more
Hide details
Innovation 'Elevator Pitch':
The MyCognition App is co-designed with patients and trialled with academics to monitor, prevent and treat mental well-being by measuring, monitoring and improving cognitive health.
Overview of Innovation:
Cognitive functioning (attention, episodic memory, executive function, working memory and processing speed) are tightly linked with mental health.  Research shows that cognitive deficits are significant predictors and major risk factors for mental illness e.g. depression, anxiety and stress. Poor cognitive health has a negative impact on our emotions, our coping strategies and tendency to ruminate and catastrophise. Alternatively, robust cognitive health contributes to building good psychological resilience, self-management and control, which are major protective factors for prevalent mental diseases. Cognition deficit affects all ages. It is manifest in young children and adolescents affecting school performance and mental well-being. It is also prevalent in preretirement populations where patients present with unexplained symptoms often categorised as psychosomatic.


MyCognition App provides digitally delivered assessment, cognitive training, coaching and behavioural change programmes. It is an easy to use and patient friendly app that can be used with any device. It is a fun and engaging App designed for all age groups for use in everyday settings.
The App has three programmes:
  1. MyCQ™ – a five-domain, 15 minute, cognitive assessment tool based on a clinically validated version.
  2. AquaSnap™ – a fun cognitive training tool, programmed by MyCQ to train all five cognitive domains. The training is personalised, designed to improve and boost an individual’s cognition where they have greatest need.
  3. A digitally delivered coaching programme to raise awareness of cognitive health and to educate and train people in healthy habits encouraging positive behavioural change.
The MyCognition App is a resource which patients can use remotely in their own homes, in residential stay or whilst in hospital. It is scalable across the whole patient community to support cognitive health. It can also be deployed in secondary care environments to support in-patient stays, occupational therapy and rehabilitation patients; and be recommended for use to patients entering step-down-care into the community, e.g. oncology and critical care.
 
The App also provides carers and professionals with personalised reports showing the cognitive health of individuals and of patient cohorts vs the general population, alerts on patients at risk and progression over time. We recommend patients and their family members/carers also use the App to encourage social interaction and shared experiences.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Digital health / Person centred care
Benefit to NHS:
MyCognition offers a self-care digital solution to assess, monitor and treat mental health and well-being by addressing a person’s cognitive health. The MyCognition App improves cognitive function in as little as eight weeks and improves mental resilience and mental health symptoms across a range of mental health disorders. From studies with patients with conditions, such as Depression, Anxiety, Schizophrenia, Post-traumatic Stress Disorder, as well as Parkinson’s and cancer-related cognitive impairment.
 
MyCognition is a self-care solution that patients can use remotely in their everyday lives to help address their mental well-being. It is ideal for use in patient waiting to be refereed to NHS services where is there is extended waiting time. It is also suitable for patients in residential stay. It is scalable across the whole patient community to support cognitive health in a range of disease areas. It can also be deployed in secondary care environments to support in-patient stays, occupational therapy and rehabilitation patients; and be recommended for use to patients entering step-down-care into the community, e.g. oncology and critical care.
 
Evidence
MyCognition has led five years of research in clinics and local institutions, demonstrating the validity of the assessment and training paradigms adopted and the positive outcomes on users’ cognition, mental health, and consequent quality of life. MyCognition is collaborating with major international universities and clinics, such as Amsterdam Medical Centre (NL), Maastricht UMC+ (NL), UZA Antwerp (BE), McGill University (CA), UCL and the Royal Free Hospital Children’s School in London. We are running studies with patients with different mental health conditions, such as Depression, Anxiety, Schizophrenia, Post-traumatic Stress Disorder, as well as Parkinson’s disease and cancer-related cognitive impairment.
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
MyCognition is committed to preventing and treating mental illness. Our strategy is aligned with the West Midlands Mental Health Strategy Boards recommendations in its 2017 report ‘Getting It Right First Time’ Prevention of Mental Illness. 
The 2017 Report by the West Midlands Mental Health Commission states that over 25% of the West Midlands population is suffering from mental illness. It highlights that people with an increased risk of developing mental health problems and/or for whom access to effective help is problematic are:
  • Unemployed people
  • People with long-term physical health conditions
  • Carers
  • Young children of school age*
  • Homeless people and people living in poor quality housing
  • People from Black, Asian and Minority Ethnic communities - Lesbian, Gay, Bisexual and Trans people
  • People with disabilities, including learning difficulties and sensory impairments
  • Young people leaving care
  • Survivors of sexual, emotional and physical abuse
  • People experiencing severe and multiple disadvantage.
*50% of mental health problems start before the age of 14 and 75% before 18
The aggregate economic and social cost of mental health problems in the WMCA is estimated at around £12.6 billion in 2014–15, equivalent to a cost of about £3,100 per head. With 28% being directly attributed to care costs of the NHS and Social Services costs. The employment costs are rising and equate to £4 billion per annum with human cost accounting for £5 billion. 
MyCognition have designed its technology to be integrated with NHS healthcare, social care, educational and workplace systems to help provide accessible self-care support for populations across the West Midlands. We wish to work with stakeholders to ensure there are as many community touchpoints for MyCognitions as possible. And provide adequate prevention and triage for at risk populations so they can reduce their risk of mental health development and deterioration.
MyCognition offers low cost personalised support to help these people deal with their mental illness. Offering them the opportunity to self-care, manage and reduce their symptoms and avoid ‘crashing’ in to the NHS for more serious and costly intervention. And more importantly lead productive and fulfilled lives.
Current and planned activity: 
Current:
MyCognition is working with several AHSNs evaluating the App in various clinical scenarios & patient pathways (rep. early 2019). Plans to roll out these clinical models with AHSNs’ support across the NHS.
 
Engaged in NHS test bed wave 2 programme and in discussions to test suitability for addressing mental health & wellbeing in schools, supporting referral to CAMS and adult mental health services, treatment of medically unexplained symptoms & diabetic self-care.
 
Running UK studies with NIHR, extending evidence base for MyCognition and also contributing to the global evidence base linking cognitive, physical & mental health.

Required:
Wish to test App & Platform’s performance in several clinical settings & pathways with West Mids. partners to generate additional data & build successful business models for NHS
  • like assistance with Procurement/Adoption & contracting with CCGs
  • further studies, seeking research partners to assist in NIHR funding proposals
What is the intellectual property status of your innovation?:
MyCognition is unique in the market place. We have full copyright of the code written for the app.

MHRA CE Marked Medical Device
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Innovation 'Elevator Pitch':
Medopad's remote monitoring platform provides clinicians with insight into patient progress in between clinic appointments. This can prevent unncessary outpatient appointments or bring forward appointments for patients who are not progressing well. 
Overview of Innovation:
The Medopad app is a health ecosystem with a patient view and a clinician view. It is very intuitive and user-friendly, having been designed with Apple in their Cupertino, California labs. 

Patient app
Patients interact with Medopad through a single smartphone app or via connected devices and sensors. Instead of multiple apps for each disease, patients have a single, centralised point of access via the Medopad platform. The Medopad app is composed of different modules and divided into four user-friendly and intuitive sections: patient profile, data collection, patient dashboard, and learning & education. Medopad provides 100+ data collection modules ranging in functionality: medication and symptom trackers, photo and video capture, tele-consultation, and questionnaires. We also provide activity-based modules for specific disease indications including the 6-minute walk test, used by cardiovascular patient cohorts to avoid travel into clinic. We can also integrate devices and sensors, i.e. glucometers and spirometry. To enable self-management, we can provide in-app videos and digital leaflets for patient education. Equally important, patients have access to their dashboard, providing a visually engaging view of trends in their own health and wellbeing data.

Clinician dashboard
The Medopad platform is built specifically for each clinician and their patient cohort via a custom integration. Clinicians monitor and manage their patient cohort through a web-based dashboard, where they can view trends in patient data that otherwise were not available to them before. Empowered with increased information, stakeholders can create customised alerts to identify patients who are progressing poorly. By extension, data availability allows clinicians to provide a high level of personalisation in between clinic appointments by sending patients customised notifications to support self-management.

 
 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Medopad's solution enables clinicians to spot health deterioration sooner, preventing costly complications.  To name a few, we are working the Royal Free NHS Teaching Hospital, Guy's and St. Thomas's, Royal Salford, and Chelsea and Westminster.

At Guys' and St. Thomas' hospital, we are working with both community nurses and hospital vascular consultants to monitor venuous leg ulcer healing. While there are no estimates for the total cost burden of venous leg ulcers specifically, the total cost of acute and chronic wounds to the UK NHS is estimated to range from £4.5 to £5.1 billion, with 78% of costs falling on community NHS services for chronic wounds (Guest et al 2015). This pilot is currently underway. Patient's leg ulcers are photographed by themselves or the community nurse during wound dressing changes. Patients' acitivity is also tracked, as increasing mobility is a sign of a healing leg ulcer. This pilot is being used by vascular consultants to identify deteriorating wounds earlier, which may necessitate a move from a community-based management to hospital-based interventions. 

At the Royal Salford, we are working with consultants to monitor patients with renal disease. In this pilot, patients are completing tasks at home that would normally be done by the nurse. Specifically, patients are monitoring weight, blood pressure, and completing a urine test at home using Healthy IO's urine dip stick test. This saves the nures time when the patient does travel into clinic, where the nurse needs only complete the remaing blood test. Apart from saving nurses time during clinic, renal consultants are able to monitor patient progress in between appointments. If patients' blood pressure and weight are not deteriorating, the consultant may postpone the appointment, and equally, if indicators seem to be worsening, the consultant can provide timely care by bringing the patient in sooner. Renal disease is a costly condition; the NHS in England spent an estimated £1.45 billion on CKD in 2009–10. By monitoring patient progress, there is potential to reduce some of these costs by reducing disease progression and complications. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The Medopad platform provides clinicians with insight into patient progress in between clinic appointments, this has the potential to provide patients with preventative and timely care by spotting problems sooner (as described in the previous section). For the patient, prevention of further deterioration means improved quality of life. Additionally, the platform has the potential to reduce unnecessary clinic appointments for patients.

At the Royal Free, patients with peripheral arterial hypertension (PAH - a rare disease) are using the Medopad smartphone to avoid travelling into clinic for appointments. Instead, patients complete a six-minute walk test (a measure of disease progression) at home. Since it can be done from home, patients can do this more frequently, on a weekly basis, which provides clinicians with richer data on which to assess patient progress. Due to the nature of the condition, PAH patients suffer from symptoms like breathlessness that are made worse with activity. By avoiding long distance travelling to one of seven specialist PAH centres, patients' health is improved and they have a better experience of care. 

At the Harley Street Clinic, we have worked with children that have a rare form of brain cancer (DIPG). Parents recorded videos of their child performing certain tasks and recorded additional health data. The clinician was able to more frequently monitor the children's progress without putting additional undue strain on both parent and child. Using the platform in this way was particularly improtant for vulnerable patients, such as these children, not to mention reducing the burden on parents.  
Current and planned activity: 
As mentioned in the previous sections, our solution and deployments have been co-developed with clinical experts and innovators across several top UK NHS teaching hospitals. 

We are currently looking for partners in the West Midlands, such as the AHSN, clinicians, and nurses, to engage in several pilot projects across a range of disease areas. Medopad is offering pilot projects free of charge for 12 months as a way to gather evidence of effectiveness and cost-effectiveness for our solution. As a part of the project, we include implementation and ongoing support.

In the longer term, we are looking to provide a transformative experience of care by providing intelligent and AI-powered clinical support systems to move the needle from reactive to preventative care. In that vein, we are looking for motivated and committed health care professionals to work with us in this journey. 
What is the intellectual property status of your innovation?:
Medopad's IP is related to its smartphone app and clinician web-portal. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
6
2
Votes
-99999

Created by

Share and Follow